Grous Beth 4

What Happened

• Beth Grous, Chief People Officer of Generate Biomedicines (GENB), made two transactions reported on the Form 4. On 2026-03-02 she purchased 300 shares in an open-market transaction at $16.00 per share for a total of $4,800. On 2026-02-26 she received a grant recorded as 114,020 derivative shares (an option award) with no dollar amount reported.

Key Details

• Open-market purchase: 300 shares at $16.00 each on 2026-03-02 — total cost $4,800.
• Grant/award: 114,020 derivative shares (option) dated 2026-02-26, reported with $0 price; footnote clarifies vesting.
• Vesting note: The option’s underlying shares vest in 48 equal monthly installments beginning after February 19, 2026, contingent on continued service.
• Shares owned after the transactions: not specified in the provided filing excerpt.
• Filing timing: Form filed 2026-03-02 covering transactions dated 2026-02-26 and 2026-03-02; readers should note reporting deadlines for insiders when considering timeliness.

Context

• The 114,020 entry is a derivative award (an option) that vests over four years; these shares are not immediately transferable unless vested and exercised. The 300-share open-market purchase is a direct buy and represents a small-dollar insider purchase. Purchases can be one data point investors use to gauge insider sentiment, but they do not by themselves indicate company performance or intent.